CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this company have returned -15.7%, compared to the Zacks S&P 500 composite's +1.3% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which CRISPR Therapeutics falls in, has gained 0.8%. The key question now is: What could be the stock's fut ...

As investors, we are always aiming to reevaluate our portfolios and make additions. However, we can often get lost in the vastness of the markets when deciding on just a handful of companies. A great place to solve this dilemma is by looking at what other investors are choosing. What better place to start than looking for the best Cathie Wood stocks to buy? After all, she is one of the most famous and respected investors. If she has done the work of rigorously analyzing these companies to put into the holdi ...

CRISPR Therapeutics (CRSP) reported earnings of $1.43 per share in the first quarter of 2024, surpassing the Zacks Consensus Estimate of a loss of $1.63. In the year-ago period, the company had incurred a loss of 67 cents per share.The company’s total revenues, generated entirely from grant revenues, were $0.5 million in the first quarter. The reported figures significantly missed the Zacks Consensus Estimate of $8.3 million. In the year-ago quarter, the company generated revenues worth $100 million, which ...

ZUG, Switzerland and BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Bank of America Securities Health Care Conference on Wednesday, May 15, 2024, at 12:20 p.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's w ...

ZUG, Switzerland and BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Bank of America Securities Health Care Conference on Wednesday, May 15, 2024, at 12:20 p.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's ...

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.43 per share versus the Zacks Consensus Estimate of a loss of $1.63. This compares to loss of $0.67 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 12.27%. A quarter ago, it was expected that this company would post a loss of $0.40 per share when it actually produced earnings of $1.10, delivering a surprise of 375%.Over the last four quarters, the company has s ...

S S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37923 CRISPR THERAPEUTICS AG (Exact name of registrant as specified in its charter) Switzerland Not Applicable (State or other juris ...

财务状况 - CRISPR Therapeutics在2024年第一季度的现金、现金等价物和可市场证券为21.08亿美元，较2023年底的16.957亿美元增加[19] - CRISPR Therapeutics AG总收入为504,000美元，较去年同期减少99.5%[38] - 现金及现金等价物为707,427,000美元，较上一季度增加81.6%[38] 研发进展 - CASGEVY™已在美国、英国、欧盟、沙特阿拉伯和巴林获得批准，用于治疗镰状细胞病和依赖输血的β地中海贫血[2] - CRISPR Therapeutics正在进行CTX112™和CTX131™的临床试验，分别针对CD19和CD70，跨多个适应症[6] - CTX310™和CTX320™是CRISPR Therapeutics的两个在进行中的临床试验，分别针对ANGPTL3和Lp(a)，与心血管疾病相关[10] - CTX211™是CRISPR Therapeutics用于治疗1型糖尿病的干细胞衍生治疗方案，目前正在进行I期临床试验[15] - CRISPR Therapeutics与Vertex合作开发CASGEVY™，Vertex负责全球开发、制造和商业化，与CRISPR Therapeutics分享成本和利润[25] - CTX112是CRISPR Therapeutics的下一代全基因组CAR T产品候选药物，针对CD19，正在进行临床试验[26] - CTX131是CRISPR Therapeutics的下一代全基因组CAR T产品候选药物，针对CD70，正在进行临床试验[27] 费用情况 - 研发费用为2024年第一季度的7620万美元，较2023年同期的9990万美元减少[20] - 研发支出为76,172,000美元，较去年同期减少23.8%[38] 盈亏情况 - CRISPR Therapeutics的净亏损为2024年第一季度的1.166亿美元，较2023年同期的5.31亿美元增加[23] - 总净亏损为116,591,000美元，较去年同期增加119.7%[38]

While a weakening economy and a subsequent dip in the stock market are unfortunate, they are inevitabilities. Even booming segments like the biotech sector are not immune to the general trend of recessions that Western economies experienced over the last 40 years or so. These downturns, however, provide opportunities for investors to buy stocks at lower prices. The case is the same for which biotech stocks to buy in a down market.Knowing when to buy a stock during market turmoil can be the difference betwee ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this company have returned -18.5% over the past month versus the Zacks S&P 500 composite's -4.1% change. The Zacks Medical - Biomedical and Genetics industry, to which CRISPR Therapeutics belongs, has lost 10.7% over this period. Now the key question is: Where could the stock be ...